Although TRIM21 expression in AML ranks high compared with other human cancers, its dependency score in DepMap across human cancers is relatively low when compared with UBE2N (Supplemental Figure 6, B and C) To investigate whether TRIM21 is required for AML cells, we targeted TRIM21 using RNAi or CRISPR/Cas9 approaches in human AML cell lines and patient-derived samples (Supplemental Figure 6D and Supplemental Table 10). Here, TRIM21 is linked to acute myeloid leukemia.